AbstractWe investigated the association between SLC6A3 gene polymorphisms and changes in dopamine transporter (DAT) availability after glucose loading in humans. An intravenous injection of 18F‐FP‐CIT was administered after infusion of glucose or placebo, and the emission data were acquired over 90 min in 38 healthy male participants. DAT availability expressed in terms of binding potential (BPND) was recorded. The 40‐bp variable number of tandem repeats (VNTR) in the 3′ untranslated region and two single nucleotide polymorphisms (SNPs), rs2652511 and rs2937639, in the SLC6A3 gene were genotyped. Among the 38 participants, those with a VNTR other than 10R/10R (n = 7) were excluded. The alleles of the two SNPs (rs2652511 and rs2937639) appeared to be inherited together in two fixed combinations (C–G or T–A) in 29 of 31 individuals. The BPND in the ventral striatum (VST), caudate nucleus, and putamen was not significantly different after glucose or placebo loading according to genotype. However, BPNDs from the caudate nucleus and putamen of all participants with rs2652511 CT/rs2937639 AG (n = 6) were higher after glucose loading. In conclusion, the SLC6A3 gene polymorphism is associated with the changes in DAT availability after glucose loading. DAT availability after glucose or placebo loading in the VST, caudate nucleus, and putamen did not differ according to the SLC6A3 genotype.

01 Sep 2020·Annals of Clinical and Translational NeurologyQ2 · MEDICINE

Imaging of dopamine transporters in Parkinson disease: a meta‐analysis of ¹⁸F/¹²³I‐FP‐CIT studies

Q2 · MEDICINE

ArticleOA

Author: Wagle Shukla, Aparna ; Zhang, Chencheng ; Liu, Kawai ; Kong, Yanyan ; Guan, Yihui ; Sun, Bomin

AbstractObjective18F‐FP‐CIT and 123I‐FP‐CIT are widely used radiotracers in molecular imaging for Parkinson’s disease (PD) diagnosis. Compared with 123I‐FP‐CIT, 18F‐FP‐CIT has superior tracer kinetics. We aimed to conduct a meta‐analysis to assess the efficacy of using 18F‐FP‐CIT positron emission tomography (PET) and 123I‐FP‐CIT single‐photon emission computed tomography (SPECT) of dopamine transporters in patients with PD in order to provide evidence for clinical decision‐making.MethodsWe searched the PubMed, Embase, Wanfang Data, and China National Knowledge Infrastructure databases to identify the relevant studies from the time of inception of the databases to 30 April 2020. We identified six PET studies, including 779 patients with PD and 124 healthy controls, which met the inclusion criteria. Twenty‐seven SPECT studies with 1244 PD patients and 859 controls were also included in this meta‐analysis.ResultsOverall effect‐size analysis indicated that patients with PD showed significantly reduced 18F‐FP‐CIT uptake in three brain regions [caudate nucleus: standardized mean difference (SMD) = −1.71, Z = −3.31, P = 0.0009; anterior putamen: SMD = −3.71, Z = −6.26, P < 0.0001; and posterior putamen: SMD = −5.49, Z = −5.97, P < 0.0001]. Significant decreases of 123I‐FP‐CIT uptake were also observed in the caudate (SMD = −2.31, Z = −11.49, P < 0.0001) and putamen (SMD = −3.25, Z = −14.79, P < 0.0001).InterpretationIn conclusion, our findings indicate that both 18F‐FP‐CIT PET and 123I‐FP‐CIT SPECT imaging of dopamine transporters can provide viable biomarkers for early PD diagnosis.

01 Jan 2020·Diabetes, Obesity and Metabolism

Striatal dopamine transporter changes after glucose loading in humans

Article

Author: Im, Hyung‐Jun ; Kim, Seong‐Jang ; Kim, Keunyoung ; Seo, Seongho ; Lee, Myung Jun ; Park, Jung‐Jun ; Pak, Kyoungjune ; Shin, Myung Jun ; Suh, Sunghwan ; Kim, In Joo

AbstractAimsThe dopamine transporter (DAT) actively translocates dopamine that is released from the presynaptic neurons across the membranes of nerve terminals into the extracellular space. We hypothesized that glucose loading‐induced changes in striatal DAT levels could be associated with food intake in humans.Materials and methodsAn intravenous bolus injection of 18F‐FP‐CIT was administered after infusion of glucose or placebo (normal saline), and emission data were acquired over 90 minutes in 33 healthy males. For a volume‐of‐interest‐based analysis, an atlas involving sub‐striatal regions of ventral striatum (VST), caudate nucleus and putamen was applied. DAT availability and binding potential (BPND) were measured using a simplified reference tissue method with cerebellum as the reference.ResultsThe glucose‐loaded BPND from the VST negatively correlated with body mass index (BMI), whereas the placebo‐loaded BPND from the VST did not. After loading with glucose, there were substantial increases in BPNDs: 18.3%, 71.7% and 34.0% on average in the VST, caudate nucleus and putamen, respectively.ConclusionStriatal DAT changes after glucose loading, and BMI is associated with glucose‐loaded DAT availability, not with placebo‐loaded DAT availability. DAT might have a role in the reward system of eating behavior.

100 Deals associated with 18F-FP-CIT

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	V09	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Parkinson Disease	KR	FutureChem Co., Ltd.	01 May 2008

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Essential Tremor	Discovery	-	Zionexa SAS	01 May 2020
Parkinson Disease	Discovery	-	Zionexa SAS	01 May 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


MDS2022	Not Applicable	Parkinson Disease	227	18F-FP-CIT PET	zmqakrvtjp(nzbbromqjb): hazard ratio = 2.743 (95% CI, 1.371 - 5.486), P-Value = 0.004	-	15 Sep 2022
				18F-FP-CIT PET

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

18F-FP-CIT

Overview

Basic Info

Structure

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation